

Screening and early detection of prostate cancer: PSA and beyond

Poster Session 18

Saturday, 25 March
14:15 - 15:45

Location: Room Stockholm, North Hall (Level 1)

Chairs: F. Abdollah, Detroit (US)
F.C. Hamdy, Oxford (GB)
M.J. Roobol, Rotterdam (NL)

Aims and objectives of this session

The session is aimed at addressing the multi-variable risk assessment to optimize the use of screening and early detection strategies in prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

- 234 **An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial**
By: Johnston T.¹, Lamb A.¹, Vowler S.², Xiong T.¹, Moore A.¹, Holding P.³, Herbert P.¹, Davis M.⁴, Lane A.⁴, Donovan J.⁴, Hamdy F.⁵, Neal D.¹
Institutes:¹University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, ²Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, United Kingdom, ³University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, ⁴University of Bristol, School of Social and Community Medicine, Bristol, United Kingdom, ⁵University of Oxford, Nuffield Department of Surgical Sciences, Oxford, United Kingdom
- 235 **At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study**
By: Carlsson S.¹, Arnsrud Godtman R.², Holmberg E.³, Lilja H.⁴, Månsson M.², Stranne J.², Hugosson J.²
Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Sahlgrenska Academy, Dept. of Urology, Gothenburg, Sweden, ³Sahlgrenska Academy, Dept. of Oncology, Gothenburg, Sweden, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Surgery, Malmö, Sweden
- 236 **Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic**
By: Margel D.¹, Mano R.¹, Benjaminov O.², Kedar I.³, Ozalvo R.¹, Sela S.¹, Ber Y.¹, Baniel J.¹
Institutes:¹Rabin Medical Center, Dept. of Urology, Petah Tikva, Israel, ²Rabin Medical Center, Dept. of Imaging, Petah Tikva, Israel, ³Rabin Medical Center, The Raphael Recanati Genetics Institute, Petah Tikva, Israel
- 237 **Is further screening of Asian men with low baseline prostate-specific antigen levels (⩽ 1.0 ng/ml) worthwhile?**
By: Urata S., Kitagawa Y., Mizokami A.
Institutes:Kanazawa University, Dept. of Urology, Kanazawa, Japan
- 238 **The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database**
By: Gild P.¹, Von Landenberg N.¹, Cole A.¹, Jiang W.², Lipsitz S.², Learn P.³, Sun M.¹, Choueiri T.⁴, Nguyen P.⁵, Chun F.⁶, Fisch M.⁶, Kibel A.¹, Menon M.⁷, Sammon J.⁷, Koehlmoos T.⁸, Haider A.², Trinh Q-D.¹
Institutes:¹Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery

and Center For Surgery and Public Health, Boston, United States of America, ²Brigham and Women's Hospital, Center for Surgery and Public Health, Boston, United States of America, ³Uniformed Services University of The Health Sciences, Dept. of Surgery, Bethesda, United States of America, ⁴Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dept. of Medical Oncology, Boston, United States of America, ⁵Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, ⁶University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ⁷Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, ⁸Uniformed Services University of The Health Sciences, Dept. of Preventive Medicine and Biostatistics, Bethesda, United States of America

- 239 **Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA \geq 1ng/ml?**
By: [Callerot P.](#)¹, Moineau M-P.², Cussenot I.³, Baschet F.³, L' Her J.¹, Doucet L.¹, Cancel-Tassin G.³, Cormier L.⁴, Mangin P.³, Cussenot O.⁵, Fournier G.¹, Valeri A.¹
Institutes:¹Brest University Hospital, Dept. of Urology, Brest, France, ²Brest University Hospital, Nuclear Medecine Laboratory, Brest, France, ³Tenon University Hospital, CeRePP (Centre De Recherche Sur Les Pathologies Prostatiques), Paris, France, ⁴Dijon University Hospital, Dept. of Urology, Dijon, France, ⁵Tenon University Hospital, Dept. of Urology, Paris, France
- 240 **Risk of prostate-cancer death at 20 years stratified by midlife PSA and a panel of four kallikrein markers from a representative cohort of 11,506 healthy unscreened men aged 45-74**
By: Sjoberg D.D.², Vickers A.J.², Assel M.², Dahlin A.³, Carlsson S.¹, Poon B.Y.², Ulmert D.¹, [Lilja H.G.](#)¹
Institutes:¹Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ²Memorial Sloan Kettering Cancer Center, Dept. of Biostatistics, New York, United States of America, ³Lund University, Clinical Microbiology, Malmo, Sweden
- 241 **Inclusion of mpMRI into the European Randomized study of Screening for Prostate Cancer (ERSPC) risk calculator: A new proposal to improve the accuracy of prostate cancer detection**
By: [Dell'Oglio P.](#)¹, Stabile A.¹, Gandaglia G.¹, Brembilla G.², Maga T.¹, Cristel G.², Kinzikееva E.¹, Losa A.¹, Esposito A.², Cardone G.², De Cobelli F.², Del Maschio A.², Gaboardi F.¹, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Vita-Salute University San Raffaele, Dept. of Radiology, Milan, Italy
- 242 **Head-to-head comparison of commonly used international prostate cancer risk calculators for prostate biopsy**
By: Pereira-Azevedo N.¹, [Verbeek J.](#)¹, Nieboer D.², Steyerberg E.², Roobol M.¹
Institutes:¹Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, ²Erasmus MC, Dept. of Public Health, Rotterdam, The Netherlands
- 243 **Outcomes of PSA-based prostate cancer screening among men using non-steroidal anti-inflammatory drugs**
By: [Murtola T.](#)¹, Vettenranta A.², Talala K.³, Taari K.⁴, Stenman U.-H.⁵, Tammela T.¹, Auvinen A.⁶
Institutes:¹Tampere University Hospital, Dept. of Urology, Tampere, Finland, ²University of Tampere, School of Medicine, Tampere, Finland, ³Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, ⁴Helsinki University, School of Medicine, Helsinki, Finland, ⁵Helsinki University Hospital, Dept. of Biochemistry, Helsinki, Finland, ⁶University of Tampere, School of Health Sciences, Tampere, Finland
- 244 **Decreasing screening efficacy with increasing age: Results from a population-based screening trial - Swiss ERSPC (Aarau)**
By: [Prause L.](#)¹, Wyler S.¹, Moltgen T.¹, Huber A.², Grobholz R.³, Manka L.⁴, Recker F.¹, Kwiatkowski M.¹
Institutes:¹Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, ²Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, ³Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, ⁴Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany

- 245 **Stage distribution of prostate cancer at a tertiary care oncology centre in India - reflections of an unscreened population**
By: Prakash G.¹, Bakshi G.¹, Shinde R.², Bhamre R.², Murthy V.³, Rent E.⁴, Pal M.¹, Mahantshetty U.³, Menon S.⁵
Institutes:¹Tata Memorial Hospital, Dept. of Surgical Oncology(urooncology), Mumbai, India, ²Tata Memorial Hospital, Dept. of Surgical Oncology, Mumbai, India, ³Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, ⁴AJ Shetty Hospital, Dept. of Surgical Oncology, Mangalore, India, ⁵Tata Memorial Hospital, Dept. of Surgical Pathology, Mumbai, India
- *246 **The diverse genomic landscape of low-risk prostate cancer**
By: Cooperberg M.¹, Erho N.², Chan J.³, Feng F.³, Cowan J.³, Simko J.³, Ong K.², Alshalalfa M.⁴, Kolisnik T.², Margrave J.², Aranes M.², Du Plessis M.², Buerki C.⁴, Zhao S.², Tenggara I.³, Davicioni E.², Carroll P.³
Institutes:¹University of California, Dept. of Urology, San Francisco, United States of America, ²GenomeDx, San Diego, United States of America, ³UCSF, Dept. of Urology, San Francisco, United States of America, ⁴GenomeDx, , San Diego, United States of America
- *247 **A positive digital rectal examination (DRE) does not predict prostate cancer in 45 yr old men - results from the German risk-adapted PCA Screening Trial (PROBASE)**
By: Arsov C.¹, Becker N.², Herkommer K.³, Gschwend J.³, Imkamp F.⁴, Kuczyk M.⁴, Hadaschik B.⁵, Hohenfellner M.⁵, Siener R.⁶, Kristiansen G.⁷, Antoch G.⁸, Albers P.¹
Institutes:¹University of Düsseldorf, Dept. of Urology, Düsseldorf, Germany, ²German Cancer Research Center Heidelberg, Division of Cancer Epidemiology (C020), Heidelberg, Germany, ³Technische Universitaet Muenchen, Dept. of Urology, Munich, Germany, ⁴Hanover Medical School, Dept. of Urology, Hanover, Germany, ⁵University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ⁶University of Bonn, Dept. of Urology, Bonn, Germany, ⁷University of Bonn, Dept. of Pathology, Bonn, Germany, ⁸University of Düsseldorf, Dept. of Diagnostic and Interventional Radiology, Düsseldorf, Germany